此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

新辅助治疗后乳腺癌患者内镜辅助与传统保乳手术的长期结果:随机、多中心、开放标签、非劣效性试验

With the title of "Long-Term Outcomes of endoscopic-assisted vs conventional breast-conserving surgery in breast cancer patients after neoadjuvant therapy: a randomized, multicenter, open label, non-inferiority trial", this study targets breast cancer patients after neoadjuvant therapy. A total of 804 eligible patients, after screening with inclusion and exclusion criteria, will be randomly assigned to Endoscopic-assisted breast conserving surgery(E-BCS) or conventional breast conserving surgery (C-BCS) group at a 1:1 ratio using stratified block randomization method, stratified by centers and molecular subtype. The co-primary endpoints are 5-year disease-free survival (5y-DFS) and Breast-Q score at 6 months after surgery. The secondary endpoints are cosmetic outcomes including surgeons' satisfaction with breast and patients' satisfaction with scar, survival outcomes including 5-year overall survival (5y-OS) and 5-year local-recurrence rate (5y-LRR), surgical outcomes including operative time, intraoperative blood loss, incision length and postoperative complications rate. This study aims to confirm the long-term safety and aesthetic outcome of endoscopic-assisted surgery in breast cancer patients after neoadjuvant treatment by comparing it with conventional open breast conserving surgery, and provide clinical evidence for the popularized application of endoscopic breast surgery.

研究概览

地位

招聘中

干预/治疗

研究类型

介入性

注册 (估计的)

804

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

学习地点

    • Guangdong
      • Guangzhou、Guangdong、中国、510120
        • 招聘中
        • Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
        • 接触:
      • Shantou、Guangdong、中国
        • 尚未招聘
        • Sun Yat-sen Memorial Hospital of Sun Yat-sen University Shenzhen Shantou Central Hospital
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 75年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

女性

描述

Inclusion Criteria:

  1. Age ranging from 18 to 75 years
  2. Pathologically confirmed invasive breast cancer
  3. Receiving preoperative chemotherapy (Each molecular subtype corresponds to unanimous regimen)
  4. cT1-3N0-3M0
  5. Unilateral breast tumor
  6. Eastern Cooperative Oncology Group score 0-1
  7. Left Ventricular Ejection Fraction (LVEF) ≥50%
  8. Leukocytes ≥ 3.0×109/L, Absolute neutrophil count ≥ 1.5×109/L, Platelets ≥ 100×109/L, Hemoglobin ≥ 90g/L, Creatinine <1.5 × institutional ULN, Total bilirubin ≤ 2.0 × institutional ULN.

Exclusion Criteria:

  1. Diffusely disseminated malignant calcification foci
  2. Not applicable for BCS after neoadjuvant therapy
  3. Pregnancy or breastfeeding
  4. Additional malignancy
  5. Severe cardiopulmonary, liver or kidney dysfunction or other systemic diseases (such as uncontrolled chronic heart failure, critical hypertension or diabetes with poor blood glucose control).

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:内镜保乳手术(E-BCS)组

comparison of 2 surgical procedures

无干预:传统保乳手术(C-BCS)组

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
5-year disease free survival
大体时间:From surgery to the end of follow-up at 5 years

The proportion of patients remaining after excluding patients with disease recurrence, metastasis or death from the time of surgery to 5-year follow-up

From surgery to the end of follow-up at 5 years
Patients' satisfaction with breast
大体时间:From surgery to the follow-up at 6 months

The score of Breast-Q scale "Satisfaction with breasts" table 6 months after surgery

From surgery to the follow-up at 6 months

次要结果测量

结果测量
措施说明
大体时间
Surgeons' satisfaction with breast
大体时间:From surgery to the follow-up at 6 months

Surgeons evaluate the cosmetic outcome of breast based on the photos before surgery and after surgery. Four ranks: Excellent (9-10 points), Good (7-8 points), Fair (5-6 points) and Poor (0-4 points) are categorized on a basis of average total score from Ueda scale

From surgery to the follow-up at 6 months
Patients satisfaction with scar
大体时间:From surgery to the follow-up at 6 months

Scar-Q scale including 3 tables about the surgical scar: appearance, symptom, psychosocial impact with total score of 100 will be used for evaluating patients satisfaction with scar

From surgery to the follow-up at 6 months
5-year overall survival
大体时间:From surgery to the end of follow-up at 5 years

The proportion of patients remaining after excluding patients who died from any cause at 5-year follow-up

From surgery to the end of follow-up at 5 years
5-year local-regional recurrence rate
大体时间:From surgery to the end of follow-up at 5 years

The proportion of patients with a lump found on breast, axilla, chest wall, skin or scars of surgery ipsilateral to the surgical side through physical examination or imaging, confirmed as the same pathological type as the primary tumor according to biopsy at 5-year follow up

From surgery to the end of follow-up at 5 years
Postoperative complication rate
大体时间:From surgery to the follow-up at 12 months

The proportion of patients with postoperative complications including hemorrhage, incision dehiscence, upper limb lymphedema, infection,seroma.

From surgery to the follow-up at 12 months
Surgical duration
大体时间:Intraoperative

The time from the beginning of surgery to the end of surgery

Intraoperative
Intraoperative blood loss
大体时间:Intraoperative

The blood loss during the operation

Intraoperative
Incision length
大体时间:Intraoperative

The length of surgical incision

Intraoperative

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 学习椅:Shicheng Su, Doctor、Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2024年8月1日

初级完成 (估计的)

2033年1月1日

研究完成 (估计的)

2033年1月1日

研究注册日期

首次提交

2024年11月29日

首先提交符合 QC 标准的

2024年12月3日

首次发布 (实际的)

2024年12月4日

研究记录更新

最后更新发布 (实际的)

2026年9月30日

上次提交的符合 QC 标准的更新

2026年9月27日

最后验证

2026年5月1日

更多信息

与本研究相关的术语

其他相关的 MeSH 术语

其他研究编号

  • SYSKY-2024-648-01

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅